Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The PUMCH Dementia Cohort is a hospital-based, observational study of Chinese elderly with cognitive impairment.
In China, the burden of dementia is increasing, which has a major impact on medical care, society, and the economy. In order to solve this important public health problem, a cohort study of cognitive impairment in the elderly should be carried out. We designed an age stratified dementia cohort and tried to to clarify the risk and prognostic factors, disease characteristics, cognitive evaluation, biomarkers, diagnosis, treatment of dementia and its subtypes in China. It is of great significance to establish a relatively comprehensive dementia database, improve the level of clinical diagnosis and treatment of cognitive impairment, and formulate prevention and treatment strategies for dementia.
Baseline data collection and cohort establishing: Detailed clinical information including demographic data, clinical history, past history and physical examination are collected. Formatted neuropsychological battery is used in all patients, including screening tests (MMSE, MoCA-PUMCH, ADL, HAD) and domain specific evaluation (Memory, executive function, visual spatial, calculation, language). Samples including serum, CSF, urine, skin, saliva are stored. Every patient is followed up every 6 months. Autopsy brain tissue will be collected if patients died.
The main contents of this study are following:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Early onset dementia | Dementia patients with onset age lower than 65y/o | ||
| Late onset dementia | Dementia patients with onset age between 65y/o and 85y/o | ||
| Oldest old dementia | Dementia patients with onset age older than 85y/o | ||
| Cognitive normal control | Normal Aging with normal cognitive function |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| The incidence of dementia | Through follow up of cognitive normal control ,to find the incidence of dementia in PUMCH cohort | Through study completion,an average of 10-20 years |
| The relationship between lifestyles, stress (stressful events and their degree) and dementia | Analysis of the relationship between lifestyles, stress and progression of dementia. Discover lifestyle factors (such as diet, residential environment, physical activity, hobbies, and sleep) and stress (stressful events and their degree) by using a questionnaire designed by PUMCH | Through study completion,an average of 10 years |
| Risk factors for dementia | Collect the risk factors in normal control and analysis the relationship after diagnosis of dementia | Through study completion,an average of 10-20 years |
| Cognitive decline | Use a systematic neuropsychological battery designed by PUMCH | Through study completion,an average of 10-20 years |
| Functional decline | Use Activity of Daily Living Scale(ADL) | Through study completion,an average of 10-20 years |
| Changes in the Neuropsychiatric Index (NPI) | In dementia patients, analysis their behavioral and psychological symptoms and the related factor. Discover the relationship between behavioral and psychological symptoms and biomarkers for dementia. | Through study completion,an average of 10 years |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
We included age stratified dementia (early onset, late onset, oldest old) , including AD, FTD,VaD, DLB and mixed dementia. Also we include cognitive normal controls.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Chenhui Mao, Doctor | Contact | +86018611895308 | maochenhui@pumch.cn | |
| Jing Gao, Doctor | Contact |
| Name | Affiliation | Role |
|---|---|---|
| Chenhui Mao, Doctor | Peking Union Medical College Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Peking Union Medical College Hospital | Recruiting | Beijing | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 29653606 | Background | Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R; Contributors. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018. | |
| 27068280 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003704 | Dementia |
| D015140 | Dementia, Vascular |
| D020961 | Lewy Body Disease |
| D000093902 | Mixed Dementias |
| D000544 | Alzheimer Disease |
| D008224 | Lymphoma, Follicular |
| ID | Term |
|---|---|
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D019965 | Neurocognitive Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
blood, CSF,urine,skin tissue, brain tissue
| Changes in the Hospital Anxiety and Depression scale (HAD) |
In dementia patients, analysis their behavioral and psychological symptoms and the related factor. Discover the relationship between behavioral and psychological symptoms and biomarkers for dementia. |
| Through study completion,an average of 10 years |
| Changes in the Cornell Scale for dementia | In dementia patients, analysis their behavioral and psychological symptoms and the related factor. Discover the relationship between behavioral and psychological symptoms and biomarkers for dementia. | Through study completion,an average of 10 years |
| Tau and Beta-amyloid biomarkers in CSF | Concentration ( pg/mL) of beta-amyloid, tau and phospho-tau in cerebrospinal fluid (CSF) of patients with dementia and controls | Through study completion,an average of 10 years |
| Tau biomarkers in serum | Concentration ( pg/mL) of tau in serum of patients with dementia and controls | Through study completion,an average of 10 years |
| CSF collection for assessing new dementia biomarker | Use collected CSF to assess new biomarkers. | Through study completion,an average of 10 years |
| Serum collection for assessing new dementia biomarker | Use collected serum to assess new biomarkers. | Through study completion,an average of 10 years |
| Urine collection for assessing new dementia biomarker | Use collected urine to assess new biomarkers. | Through study completion,an average of 10 years |
| Skin collection for assessing new dementia biomarker | Use collected skin for finding new biomarkers. | Through study completion,an average of 10 years |
| Biomarker differences of dementia | The differences of biomarkers in patients with different dementia. | Through study completion,an average of 10 years |
| Incorporating age stratified biomarkers into the diagnosis of dementia | Comparing the relationships between biomarkers and clinical presentations. Incorporate biomarkers into the accurate and early diagnosis of dementia | Through study completion,an average of 10 years |
| Dementia education and training | Observe the function of education and training in the treatment and care of dementia patients | Through study completion,an average of 10 years |
| Dementia diagnosis system and evaluation system | Use machine learning methods to establish computer-assisted dementia diagnosis system and evaluation system. Establish prediction models for the progression of dementia | Through study completion,an average of 10 years |
| Background |
| Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, Holtta M, Rosen C, Olsson C, Strobel G, Wu E, Dakin K, Petzold M, Blennow K, Zetterberg H. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016 Jun;15(7):673-684. doi: 10.1016/S1474-4422(16)00070-3. Epub 2016 Apr 8. |
| 25030513 | Background | Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol. 2014 Aug;13(8):788-94. doi: 10.1016/S1474-4422(14)70136-X. |
| 11708987 | Background | McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ; Work Group on Frontotemporal Dementia and Pick's Disease. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol. 2001 Nov;58(11):1803-9. doi: 10.1001/archneur.58.11.1803. |
| 29055814 | Background | Rosenberg A, Ngandu T, Rusanen M, Antikainen R, Backman L, Havulinna S, Hanninen T, Laatikainen T, Lehtisalo J, Levalahti E, Lindstrom J, Paajanen T, Peltonen M, Soininen H, Stigsdotter-Neely A, Strandberg T, Tuomilehto J, Solomon A, Kivipelto M. Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: The FINGER trial. Alzheimers Dement. 2018 Mar;14(3):263-270. doi: 10.1016/j.jalz.2017.09.006. Epub 2017 Oct 19. |
| 39738784 | Derived | Yang X, Wu M, Liang M, Zhang H, Li B, Mao C, Dong L, Wang Y, Xing H, Ren C, Huang Z, Wen Q, Ge Q, Yu Z, Feng F, Gao J, Huo L. Ultra-fast [18F]florbetapir PET imaging using the uMI Panorama PET/CT system. EJNMMI Phys. 2024 Dec 30;11(1):107. doi: 10.1186/s40658-024-00712-5. |
| D001523 | Mental Disorders |
| D002561 | Cerebrovascular Disorders |
| D002537 | Intracranial Arteriosclerosis |
| D020765 | Intracranial Arterial Diseases |
| D056784 | Leukoencephalopathies |
| D001161 | Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |
| D024801 | Tauopathies |
| D008228 | Lymphoma, Non-Hodgkin |
| D008223 | Lymphoma |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |